cyrilzakka/clinical-trials huggingface dataset:
Closed Window vs. Open Window Technique in Management of Palatally Impacted Canines

In this investigation the investigators would like to find out which of two commonly used techniques of management of palatally impacted canines: closed-window (CWT) or open-window (OWT), produces more favorable outcome.

Rationale and objective: Two techniques for exposing palatally impacted canines are routinely used, the closed window technique (CWT) and the open window technique (OWT). To our knowledge, there is no evidence-based information that would suggest, which of the two techniques results in a better outcome. Our null hypothesis is that there is no difference in the outcome of exposed impacted maxillary canines after CWT or OWT.

Study design: A randomized clinical multicentre trial with a two-group design. The randomization is by canine, not by patient.

Study population: The case group consists of healthy persons of 11-17 years old who have unilateral palatally impacted canines.

Intervention: One group will be treated with the CWT and the other group with the OWT.

Main study parameters/endpoints: The main outcome measure will be the total duration of treatment (including also orthodontic treatment) with two techniques of management of impacted canines. The secondary outcome measures will be: (1) duration of surgical procedure, (2) patients perception of pain and recovery after surgery, (3) burden of care, (4) cost-effectiveness, (5) quality of life and satisfaction with treatment, (6) degree of root resorption of the lateral incisor, (7) periodontal status of impacted canine and adjacent teeth, (8) esthetic outcome, (9) need for endodontic treatment of the impacted canine or adjacent lateral incisor, (10) occlusal outcome (evaluated with PAR index).

Nature and extent of the burden and risks associated with participation, benefit and group relatedness: The CWT and OWT are current treatment techniques. To our knowledge, there is no sound scientific information available on which to base a treatment decision. The burden of each treatment is for the patient the same. Routine pre- and post-treatment records will be taken. The extra burden for the patients participating in the trial will be records and questionnaires during treatment and long-term

Eligibility Criteria:
Inclusion Criteria:

* Healthy boys and girls aged 11 to 17 years
* Unilaterally palatally impacted canine
* Canine axis \> 100 to the midline measured on an orthopantomogram

Exclusion Criteria:

* Dental abnormalities (hyperdontia, hypodontia, etc.)
* Previous dental or facial trauma
* Congenital craniofacial disorder
Application of Overlap Method to Digestive Tract Reconstruction of Totally Laparoscopic Left Colectomy

Objective:The comparison between total laparoscopic colectomy with intracorporeal anastomosis by overlap method and laparoscopic-assisted colectomy with extracorporeal anastomosis for colon cancer surgery.

Condition or disease：Left colon cancer Intervention/treatment： Procedure:Intracorporeal left colectomy Overlap anastomosis Procedure: Extracorporeal left colectomy convention anastomosis

This a simple randomized, single-center, single-blind, randomized controlled trial study.The patients were randomly divided into experimental groups and control groups by computer.The perioperative recovery data, complications and oncology index of total laparoscopic colectomy with intracorporeal anastomosis and laparoscopic-assisted colectomy with extracorporeal anastomosis would be compared.

Eligibility Criteria:
Inclusion Criteria:

* ASA\<3 classification
* 18kg/m2≤BMI≤30kg/m2
* Neoplasm staging is T1-4a, N0-2, M0
* No previous history of abdominal surgery
* No previous history of neoplasm chemoradiotherapy
* No status of ileus, bowel obstruction and active hemorrhage of the digestive tract

Exclusion Criteria:

* Age\<18 years or \>75 years
* ASA≥3 classification
* BMI\<18kg/m2 or BMI\>30kg/m2
* Neoplasm staging is T4b or M1 Underwent chemoradiotherapy Appeared status of ileus,bowel perforation or active hemorrhage of digestive tract Patients with pregnant
Use of Ceftaroline in Hospitalized Patients With Community Acquired Pneumonia

Community-acquired bacterial pneumonia, which is often called CAP, is a bacterial infection in the lungs and is treated with antibiotics. Sometimes people need to be in the hospital to be treated for CAP. Usually, hospitalized persons with CAP are given two antibiotics together. These antibiotics usually include a cephalosporin and a macrolide. The most commonly used cephalosporin at Albany Medical Center Hospital is ceftriaxone. The most commonly used macrolides at Albany Medical Center Hospital are azithromycin and doxycycline.

This research is being done to find out how well a new cephalosporin antibiotic, called ceftaroline, works in combination with a macrolide for the treatment of CAP. Ceftaroline is similar to ceftriaxone. Ceftaroline was recently approved by the FDA to treat pneumonia in hospitalized patients based on two research studies. In one study, ceftaroline was better than ceftriaxone. In the second study, ceftaroline was just as good as ceftriaxone. Ceftaroline was very well tolerated in both clinical studies and it was found to be as safe as ceftriaxone.


Eligibility Criteria:
Inclusion Criteria:

* age 18 years or older
* met ATS/ISDA criteria rule of CABP
* CABP requiring hospitalization and treatment with a IV antimicrobial
* anticipated hospitalization for \> 48 hours
* received ceftaroline in combination with a macrolide (clarithromycin, or azithromycin) for \> 48 hours within the first 24 hours after presentation to the hospital and must have remained on therapy for at least 48 hours after admission
* Pneumonia Patient Outcomes Research Team (PORT)risk class III or IV

Exclusion Criteria:

* CABP PORT Risk class I, II, III
* CABP requiring admission to an ICU
* CABP suitable for outpatient therapy with an oral microbial agent
* confirmed or suspected respiratory tract infection attributed to a source other than CABP pathogens
* noninfectious case of pulmonary infiltrates or pleural empyema
* infection with a pathogen know to be resistant to ceftaroline or epidemiological/ clinical context suggesting a high likelihood of a resistant pathogen
* previous therapy with another intravenous beta-lactam for CABP for between 24 and 96 hours prior to randomization
* receipt of chronic concomitant systemic steroids \> 40 mg of prednisone equivalent
* significant hepatic disease
* hematologic disease
* Immunological disease
* history of a hypersensitivity reaction to beta-lactams
* pregnant or nursing females
Effects of Retro-walking in Patients With Knee OA

Osteoarthritis is degenerative joint disease that cause deterioration of the articular cartilage and neighboring tissue and lead to osteophyte formation, weakening of surrounding muscles, ligamentous laxity and inflammation of synovium. Diagnosis can be made based on history and clinical features and risk factors including age, sex, body mass index , absence of whole leg pain, fixed flexion deformity, absence of traumatic event, restricted flexion range of motion, pain in descending stairs, palpable effusion and crepitus. Confirmation is usually based on radiological finding according to Kellgren and Lawrence diagnostic scale . Radio graphic changes of osteoarthritis of the knee are bilateral in 85% of patients .

Knee pain is a major symptom of knee osteoarthritis (OA) that lead to stiffness, and capsular contracture along with muscle spasm. Decreased flexibility of muscles reduces the joint range of motion and thus contributes to increase in the stiffness of the joint lead to physical disability in persons with knee OA.Eighty percent of persons with knee OA experience pain and 25% struggle to perform activities of daily living.) Retro-walking is sometimes referred to as backward walking, has been thought to be used already for several decades in China, Japan and Europe to get a physical workout, improve sport performance, promote balance and also to stay mentally fit .

In fact in Europe, they have races which vary from sprints to the 26.2 miles marathon.

Eligibility Criteria:
Inclusion Criteria:

* Unilateral Knee OA .
* Kellgren-Lawrence grading (grade 1 and 2)
* Participants fulfilling three out of the six clinical criteria listed by the American College of Rheumatology The criteria are Age \>40 years, Morning stiffness lasting \<30 mins. Crepitus with active motion, Bony tenderness, Bony enlargement and No warmth to touch and diagnosed to have knee OA
* Pain more than 6 weeks

Exclusion Criteria:

* Trauma or surgery in the last 6 months.
* Hip, knee, and foot deformities.
* Stroke and other neurovascular issues.
* Severe pain (greater than 7 in NPRS)
* Difficulty in walking for 10 min continuously.
* Obesity (body mass index greater than 25 kg/m2 )
* Osteoporosis
* Patients having any systemic joint pathology, inflammatory joint disease (e.g. rheumatoid arthritis, gouty arthritis, psoriatic arthritis).
* Patients who had any neurological deficit, myelopathy any mental illness.
Efficacy And Safety of An IRE System For Treatment of Inferior Turbinate Hypertrophy

The purpose of the IRE System is to address the clinical need for reducing the volume of hypertrophic inferior turbinate(s) causing nasal obstruction while minimizing side effects and complications. Procedure time will also be reduced. The IRE System is designed to be more comfortable for patients, as it employs a noninvasive procedure using a high voltage pulsed electric field to create irreversible nanopores in the cell membrane, leading to cell death and the reduction of the inferior turbinate volume.

The purpose of the IRE System is to address the clinical need for reducing the volume of hypertrophic inferior turbinate(s) causing nasal obstruction while minimizing side effects and complications. Procedure time will also be reduced. The IRE System is designed to be more comfortable for patients, as it employs a noninvasive procedure using a high voltage pulsed electric field to create irreversible nanopores in the cell membrane, leading to cell death and the reduction of tonsil volume. On basis of these finding and in view of the known safety profile (refer to Chen et.al ) and efficacy of current technologies, the purpose of the current study is to prospectively determine the efficacy and safety of the IRE System in interior turbinate reduction.

Eligibility Criteria:
Inclusion Criteria:

* Age 18 - 70 years.
* Nasal Obstruction Symptom Evaluation (NOSE) score of ≥ 60 at the Baseline.
* Hypertrophy of the inferior turbinate is the primary cause of the patient's nasal obstruction based on vasoconstriction test.
* Did not improve with medical treatment, including topical nasal steroids for nasal obstruction for at least three months.

Exclusion Criteria:

* Age below 18 years
* Patients with a pacemaker or similar electro stimulator
* Patients with caudal septal deviation that narrows the anterior nasal valve.
* Patients with nasal polyps/tumors.
* Patients with chronic rhinosinusitis.
* Patients with Eosinophilia
* Patients for whom the anesthesia involves high risk.
* Patients with Epilepsy or other condition involving convulsions.
* Patients with an inability to give informed consent and to complete self-reported questionnaires.
* Patients with an inability to cooperate for treatment and follow-up.
* Patients with severe heart disease.
* Pregnancy or breastfeeding.
* Previous inferior turbinate surgery.
Social and Financial Incentives to Increase Physical Activity Among Overweight and Obese Veterans

In this randomized, controlled trial the investigators will compare the use of social and financial incentive-based interventions to increase physical activity among overweight and obese Veterans during a 12-week intervention with 8 weeks of follow-up.

In this 3-arm randomized trial, the investigators will compare the effectiveness of a social incentive-based gamification intervention with and without loss-framed financial incentives to increase physical activity relative to a control among overweight and obese adults Veterans. All Veterans will use a Fitbit wearable device to establish a baseline step count, select a step goal increase of 33% to 50% above baseline and then participate in a 12-week intervention and 8-week follow-up period. The two intervention arms will be entered into a game with points and levels designed using insights from behavioral economics. They will be asked to select a social support partner who will receive weekly updates on their progress in the game. Veterans in one arm will also receive loss-framed financial incentives allocated to an account each week during the intervention and financial incentives taken away each day the step goal was not achieved.

Eligibility Criteria:
Inclusion Criteria:

* Veterans
* Body mass index of 25 or greater
* Access to smartphone or tablet to sync wearable device data
* Interest in participating in a 20-week physical activity program

Exclusion Criteria:

* Already participating in a physical activity research study
* Unable to provide informed consent
* Unsafe or infeasible to participate
* No access to smartphone or table to sync wearable device data
Evaluation of the 755nm Alexandrite for Unwanted Tattoos

The purpose of this study is to collect further data on the safety and efficacy of removing unwanted non cosmetic tattoos (including recalcitrant) using a 755nm Alexandrite laser.


Eligibility Criteria:
Inclusion Criteria:

1. Is a healthy male or female between 18 and 85 years old.
2. Has unwanted non-cosmetic tattoo(s) and wishes to undergo laser treatments to remove them.
3. Is willing to consent to participate in the study.
4. Is willing to comply with all requirements of the study including being photographed, following post treatment care and attending all treatment and follow up visits.

Exclusion Criteria:

1. Is hypersensitive to light exposure.
2. Has active localized or systemic infection.
3. Is taking medication(s) for which sunlight is a contraindication.
4. Has a history of squamous cell carcinoma or melanoma.
5. Has a history of keloid scarring.
6. Has used oral isotretinoin (Accutane®) within 12 months of initial treatment or plans on using during the course of the study. Note: Skin must regain its normal degree of moisture prior to treatment.
7. Has a history of immunosuppression/immune deficiency disorders (including HIV infection or AIDS) or use of immunosuppressive medications.
8. Is female and pregnant, has been pregnant within the last 3 months, is currently breast feeding or planning a pregnancy during the study period.
9. Is allergic to lidocaine, tetracaine or Xylocaine with epinephrine.
10. Has any other reason determined by the physician to be ineligible to participate in the study.
Japanese Study Evaluating the Effects of Telithromycin in Children With Community-Acquired Pneumonia

The primary objective is to assess the safety of telithromycin (HMR3647) 20 mg/kg qd for 5-7 days in children with community-acquired pneumonia (CAP).

Secondary objectives are to assess Pharmacokinetics, Efficacy and Acceptability of telithromycin 20 mg/kg qd for 5-7 days in children with CAP.


Eligibility Criteria:
Inclusion Criteria:

* Subjects who are weighing 40 kg or less. If female, premenarchal status is required.
* Subjects who are diagnosed with CAP based on chest X-ray showing the presence of a new infiltrate, clinical symptoms, and laboratory findings.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
The Genetics of Pulmonary Fibrosis

This study seeks to screen first degree family members of people with Idiopathic Pulmonary Fibrosis (IPF) for the earliest signs of lung fibrosis.

The purpose of this study is to explore genetic factors associated with the development of pulmonary fibrosis. The investigators aim is to identify and explore genetic loci that affect development of pulmonary fibrosis and also explore related environmental exposures. Idiopathic pulmonary fibrosis (IPF) is one of the interstitial lung diseases under the broader umbrella of idiopathic interstitial pneumonias (IIP). The investigators hypothesize that inherited genetic factors are associated with pulmonary fibrosis. To investigate the genetics of pulmonary fibrosis, the investigators plan to enroll individuals with pulmonary fibrosis and their family members.

Eligibility Criteria:
Inclusion Criteria:

* Age at least 18 years old
* Family member diagnosed with IPF

Exclusion Criteria:

- No family member with IPF
Evaluation of Vidiac Scores of Obese and Morbid Obese Patients Intubated by Videolaryngoscopy

The aim of the study was to observe the vidiac score values of only patients with obesity as a risk factor for difficult intubation. Secondly, it was aimed to evaluate the number of intubation attempts and intubation time, vidiac scores between obese and morbid obese patients and to reveal the differences, if any.


Eligibility Criteria:
Inclusion Criteria:

* All obese and morbidly obese patients to be operated under general anesthesia and endotracheal intubation

Exclusion Criteria:

1. under 18 years old
2. The patient's refusal
3. Difficult airway story before
4. Congenital or previous airway anatomical disorder
5. Patients who have undergone airway surgery
6. Patients with a mass in the head and neck region
7. Body mass ındex \< 30 kg/m2
Study to Evaluate Safety, Tolerability, PK and PD of ALXN1007 in Healthy Subjects

The purpose of the study is to evaluate the safety, tolerability, PK and PD of a single-dose of ALXN1007 in healthy volunteers.

All subjects will be screened for eligibility after providing signed informed consent. Once a subject is determined to be eligible, the subject will be vaccinated with the quadrivalent meningococcal conjugate vaccine at least two weeks prior to dosing, if applicable. A total of 7 dose cohorts will be enrolled sequentially and randomized to receive ALXN1007 or placebo. Subjects will receive ALXN1007 or placebo at the clinic and be kept at the clinic for a total of 4 days for observation and completion of the required study tests.

The subjects will return for 8 additional clinic visits to complete the required study tests over the next 86 days. The total duration of the study is 90 days from the day of dosing with ALXN1007 or placebo.

Eligibility Criteria:
Inclusion Criteria:

* Healthy individuals 25 to 55 years of age with documented vaccination with MCV4.

Exclusion Criteria:

* Abnormal renal or liver function.
* History of meningococcal disease.
* History of Guillain-Barre syndrome.
* Known infection with HIV or Hepatitis B or C.
Effect of Age on the Median Effective Concentration(EC50) for Motor Block With Spinal Plain Bupivacaine

This study was performed in 131 adult patients undergoing transurethral, urological or lower limb surgery under combined spinal and epidural anesthesia. Patients were stratified according to age: 20-30, 31-40, 41-50, 51-60, 61-70, and 71-80 years. The spinal component of the anesthetic was established by bolus administration of up-and-down doses of 0.75% plain bupivacaine, determined by Dixon's method. The degree of motor block after intrathecal administration of each concentration was evaluated by the modified Bromage and Hip motor function score. The EC50 were estimated from the up-and-down sequences using the method of Dixon and Massey and logistic regression. Other endpoints were included on the basis of sensory block level, duration of motor blockade, hypotension, and vasopressor requirements.


Eligibility Criteria:
Inclusion Criteria:

- ASA physical status I-II adult patients who were undergoing transurethral, urological or lower limb surgery, primarily under the spinal component of established combined epidural-spinal anesthesia, with the epidural component to be used if there was a need for intra-operative analgesic supplementation or for postoperative analgesia.

Exclusion Criteria:

* Patients with diabetes, obesity, neuromuscular diseases, bleeding diathesis, hypersensitivity to amide local anesthetics, lumbar vertebrae abnormality, chronic back pain, or who were pregnant were excluded from this study
Evaluation of Meibomian Gland Dysfunction Before and After Cataract Surgery

This study will compare cataract patients before and after phacoemulsification. Evaluations will be performed before and 1 and 3 months following cataract surgery, including parameters of dry eye syndrome and MGD. Dry eye syndrome parameters included TBUT, Schirmer's test type I, Oxford staining score, and the Ocular Surface Disease Index (OSDI) Questionnaire. MGD parameters consisted of lipid layer thickness (LLT), lid margin abnormality, meibum quality, meibum expressibility, MG orifice obstruction, MGD stage, and MG dropout.


Eligibility Criteria:
Inclusion Criteria:

* Patients with cataract surgery planning with phacoemulsification and intraocular lens implantation with or without mild dry eye syndrome

Exclusion Criteria:

* the previous use of eye drops, except artificial tears within 3 months before cataract surgery
* a history of previous ocular surgery or trauma
* the presence of ocular comorbidities such as glaucoma, uveitis, cystoid macular edema, and any surgical complications including rupture of the posterior capsule during cataract surgery.
Appraising Medical Trial Experiences of Ovarian Cancer Patients

Historically, participation in clinical trials has been highly skewed towards specific demographic groups. However, research identifying which trial attributes impact participation, in either positive or negative ways, is limited. This study invites participants to record a wide range of data on their clinical trial experience, with the goal being to identify factors which persistently limit patients' ability to participate in, or complete, a trial in which they were initially interested. Data will be analyzed through a range of demographic lenses, in hopes of discovering patterns which might improve the experience of future ovarian cancer patients.


Eligibility Criteria:
Inclusion Criteria:

* Aged ≥ 18 years old and ability to provide written informed consent obtained prior to participation in the study and any related procedures being performed
* Patient has been diagnosed with ovarian cancer
* Subjects willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examination.

Exclusion Criteria:

* Inability to perform regular electronic reporting
* Patient does not understand, sign, and return consent form
* Pregnant, breastfeeding or expecting to conceive within the projected duration of the study